Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 6/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CCR9 | P51686 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20121087 | 0.89 | ROCK2 (0.47) | ROCK2ROCK1KDM2BPIK3CAMTNR1A | |
| SCHEMBL18938865 | 0.83 | NOTUM (0.41) | ROCK2ROCK1NOTUMCCR9PIK3CA | |
| SCHEMBL18969559 | 0.82 | ROCK2 (0.44) | ROCK2ROCK1KDM2BMTNR1AMTNR1B | |
| SCHEMBL31215258 | 0.82 | ROCK2 (0.44) | ROCK2ROCK1KDM2BMTNR1AMTNR1B | |
| SCHEMBL28577593 | 0.81 | NOTUM (0.41) | ROCK2ROCK1NOTUMCCR9PTGER4 | |
| SCHEMBL29850057 | 0.81 | NOTUM (0.40) | ROCK2ROCK1NOTUMCCR9PIK3CA | |
| SCHEMBL29850694 | 0.81 | CCR9 (0.56) | ROCK2ROCK1NOTUMCCR9PTGER4 | |
| SCHEMBL18940655 | 0.81 | CCR9 (0.56) | ROCK2ROCK1NOTUMCCR9PTGER4 | |
| SCHEMBL18969545 | 0.81 | NOTUM (0.40) | ROCK2ROCK1NOTUMCCR9PIK3CA | |
| SCHEMBL28839575 | 0.79 | ROCK2 (0.41) | ROCK2ROCK1KDM2BNOTUMPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885342-B1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-112789087-B | Benzimidazole inhibitors of PAD enzymes | 百时美施贵宝公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-3833439-B1 | BENZIMIDAZOLE INHIBITORS OF PAD ENZYMES | BRISTOL MYERS SQUIBB CO (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220348562-A1 | BENZIMIDAZOLE INHIBITORS OF PAD ENZYMES | BRISTOL MYERS SQUIBB CO (US) | 2022-11-03 | — | — | US | disclosed |
| CN-109069869-B | Bicyclic PAD4 inhibitors | 帕德罗科治疗公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-3885342-A1 | BICYCLIC INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3885342-A1 | BICYCLIC INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3833439-A1 | BENZIMIDAZOLE INHIBITORS OF PAD ENZYMES | Bristol-Myers Squibb Company (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3386590-B1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3386590-B1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020033514-A1 | BENZIMIDAZOLE INHIBITORS OF PAD ENZYMES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-13 | — | — | WO | disclosed |
| EP-3386590-A1 | BICYCLIC INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| WO-2017100594-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100594-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADI4, PADI1, PADI2 | ROCK2 3597/4885ROCK1 3617/4885KDM2B 328/4885 |
| US-20220348562-A1 | BENZIMIDAZOLE INHIBITORS OF PAD ENZYMES | PADI4, PADI1, PADI2 | ROCK2 1949/4885ROCK1 1166/4885KDM2B 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.